Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes

NCT07165028 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07165028
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07165028 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Recruiting
Start date
October 15, 2025
Completion date
August 31, 2032
Enrollment
4,500 (estimated)
Sites
563

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated steatotic liver disease